Farhad Ravandi, MD is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
In his compelling presentation, Farhad Ravandi, MD, a distinguished medical professional in the field of oncology, delves into the critical significance of minimal residual disease (MRD) assessment in the realm of acute myeloid leukemia (AML) treatment. As an accomplished hematologist, Dr. Ravandi brings his extensive expertise to the forefront, elucidating how achieving complete morphological remission is a pivotal determinant in long-term survival for AML patients.
With the advent of cutting-edge technologies like multi-parameter flow cytometry and molecular assays, the assessment of MRD has become increasingly sophisticated, enabling the detection of even trace amounts of residual leukemia cells. Dr. Ravandi expounds upon the profound impact of MRD status on patient outcomes, demonstrating its relevance across diverse treatment modalities, including intensive and lower intensity regimens.